Results 71 to 80 of about 48,854 (243)

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing [PDF]

, 2019
PURPOSE: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters and institutions in the process
Beitelshees, Amber L., Bell, Gillian C., Bishop, Jeffrey R., Blake, Kathryn, Cavallari, Larisa H., Crona, Daniel J., Dressler, Lynn, Duong, Benjamin Q., Empey, Philip E., Gregg, Ryan A., Hicks, J. Kevin, Hines, Lindsay J., Johnson, Julie A., Lee, James C., Limdi, Nita A., Obeng, Aniwaa Owusu, Peterson, Josh F., Pratt, Victoria M., Prows, Cynthia A., Ramsey, Laura B., Scott, Stuart A., Shelton, Richard C., Skaar, Todd C., Smith, D. Max, Tuteja, Sony, Van Driest, Sara L., Weitzel, Kristin Wiisanen   +26 more
core   +1 more source

Fluoxetine: a case history of its discovery and preclinical development [PDF]

, 2014
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N, Bergstrom RF, Bravo L, Bremner JD, Burrows GD, Chouinard G, Datla KP, Esther Berrocoso, Juan Antonio Mico, Kreiss DS, Laura Perez-Caballero, Lemberger L, Li Q, Lidia Bravo, Maj J, Nibuya M, Owens MJ, Rutter JJ, Sonia Torres-Sanchez, Stevens JC, Wong DT   +20 more
core   +2 more sources

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia

Pharmacogenomics and Personalized Medicine, 2020
Monpat Chamnanphon,1 Sorawit Wainipitapong,2 Teeravut Wiwattarangkul,3 Phenphichcha Chuchuen,2 Kunathip Nissaipan,1,4 Weeraya Phaisal,1,4 Sookjaroen Tangwongchai,2 Chonlaphat Sukasem,5 Supeecha Wittayalertpanya,1,4 Andrea Gaedigk,6 Daruj Aniwattanapong,2
Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P   +11 more
doaj  

PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS

Архивъ внутренней медицины, 2018
The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment.
A. L. Khokhlov, A. N. Yavorsky, N. O. Pozdnyakov, J. V. Rybachkova, E. S. Emelianov, A. A. Khokhlov, A. E. Miroshnikov, S. O. Pozdnyakov   +7 more
doaj   +1 more source

CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids [PDF]

, 2017
Purpose When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief.
Broome, Marion E., Burke Draucker, Claire, Carpenter, Janet S., Holmes, Ann M., Knisely, Mitchell R., Skaar, Todd C., Von Ah, Diane   +6 more
core   +2 more sources

Current evidence for a modulation of low back pain by human genetic variants [PDF]

, 2009
The manifestation of chronic back pain depends on structural, psychosocial, occupational and genetic influences. Heritability estimates for back pain range from 30% to 45%. Genetic influences are caused by genes affecting intervertebral disc degeneration
Aberle, Agarwal, Agrawal, Aladin, Anderson, Andersson, Annunen, Arnold, Ashford, Atkinson, Bandell, Battie, Battie, Bautista, Bejaoui, Berthele, Beyer, Blau, Bond, Brown, Brown, Brown, Campa, Caraco, Carbonell Sala, Carragee, Cascorbi, Cho, Chou, Chou, Cipollone, Collart, Cox, Dalen, Daly, Dawkins, Dayer, Dayer, Diatchenko, Diatchenko, Diatchenko, Dick, Doehring, Eckhardt, Einarsdottir, Fillingim, Foulkes, Fu, Gasche, Goldberg, Grant, Gross, Gursoy, Gutierrez-Roelens, Hamdani, Hartvigsen, Hayashida, Hernandez, Higashino, Hirose, Hoyland, Hummel, Hustmyer, Ikeda, Indo, Irmgard Tegeder, Jayamanne, Jim, Jörn Lötsch, Kales, Kalichman, Karppinen, Karsak, Kawaguchi, Kawaguchi, Kawasaki, Khoromi, Kim, Kim, Kim, Kim, Kirchheiner, Kirchheiner, Klepstad, Knoeringer, Kroslak, Kuisma, Kung, Lafreniere, Landau, Langdahl, Le Maitre, Lee, Lettre, Leyne, Lichtman, Liem, Lorenzo, Lotsch, Lotsch, Lotsch, Lotsch, Lotsch, Lotsch, Lovlie, Lu, Luoma, Lötsch, MacDonald, Macpherson, Madadi, Manning, McNamara, Meeus, Meller, Meller, Mignat, Mio, Miura, Mogil, Mogil, Morrison, Nguyen, Noponen-Hietala, Noponen-Hietala, Oakley, Oertel, Oertel, Oertel, Ofek, Ohtori, Oliveira, Paassilta, Papafili, Pilotto, Pluijm, Poulsen, Racz, Racz, Rakvag, Ralston, Ralston, Reyes-Gibby, Richards, Riviere, Roddier, Romberg, Russo, Sachse, Sakai, Schmidt, Schneider, Seki, Seki, Sindrup, Sipe, Skarke, Skarke, Slade, Slaugenhaupt, Solovieva, Solovieva, Solovieva, Solovieva, Solovieva, Srinivasan, Srinivasan, Stamer, Stamer, Steward, Stohler, Suzuki, Svendsen, Tadic, Takahashi, Tam, Tander, Tegeder, Tegeder, Thieme, Thomas, Trevisani, Uitterlinden, Ujike, van Meurs, Vargas-Alarcon, Verhoeven, Videman, Videman, Virtanen, Voronov, Vree, Wiesinger, Yamada, Yazdanpanah, Zhang, Zhang, Zhang, Zhang, Zubieta, Zuo   +200 more
core   +1 more source

Enantioselective analysis of metoprolol in plasma of hypertensive patients undergoing long-term therapy: Insights for personalized medicine [PDF]

BioImpacts
Introduction: Metoprolol is therapeutically formulated as a racemate with stereoselective pharmacokinetics influenced by CYP2D6 polymorphism. Understanding enantioselective disposition is critical for optimizing therapy in hypertensive patients ...
Behrouz Seyfinejad, Kimiya Jouyban, Jalil Houshyar, Amirreza Jabbaripour Sarmadian, Abolghasem Jouyban   +4 more
doaj   +1 more source

Clinical applications of pharmacogenomics [PDF]

, 2017
Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution ...
Cayún, J.P., Escalante, P., Gallegos, B., Lares-Asseff, I., Meneses, F., Miranda, C., Quiñones, L., Roco, Á., Varela, N., Zaruma-Torres, F.   +9 more
core   +1 more source

Allelic variants of the cyp2d6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela

Revista Peruana de Medicina Experimental y Salud Pública, 2015
The aim of this study was to determine the CYP2D6: * 4, * 6 and * 10 gene variants frequency and to predict the metabolizer phenotype in a sample of 145 unrelated apparently healthy individuals residing in the state of Aragua, Venezuela.
Carlos Flores-Angulo, Cecilia Villegas, Yuselin Mora, José Antonio Martínez, Teresa Oropeza, Nancy Moreno   +5 more
doaj   +1 more source

Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer [PDF]

, 2007
OBJECTIVE: Xenobiotic-metabolizing enzymes are widely polymorphic and confer interindividual variation in the ability to detoxify carcinogens or to activate pro-carcinogens.
Carrilho, F, Carvalheiro, M, Coutinho, E, Gomes, L, Lemos, MC, Regateiro, FJ, Rodrigues, F   +6 more
core   +1 more source